Iron metabolism, free radicals, and oxidative injury

被引:341
作者
Emerit, J
Beaumont, C
Trivin, F
机构
[1] Hop St Joseph, Serv Biochim, F-75674 Paris 14, France
[2] Univ Paris 07, Genet & Pathol Mol Hematopoiese, INSERM, U409, F-78570 Paris 18, France
关键词
deferroxamine; free iron; oxidative stress;
D O I
10.1016/S0753-3322(01)00068-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Iron has the capacity to accept and donate electrons readily. This capability makes it physiologically essential, as a useful component of cytochromes and oxygen-binding molecules. However, iron is also biochemically dangerous; it can damage tissues by catalyzing the conversion of hydrogen peroxide to free-radical ions that attack cellular membranes, protein and DNA. This threat is reduced in the healthy state where, because of the fine iron metabolism regulation, there is never appreciable concentration of 'free iron'. Under pathological conditions, iron metabolism and superoxide metabolism are clearly interactive. Each can exacerbate the toxicity of the other. Iron overload may amplify the damaging effects of superoxide overproduction in a very broad spectrum of inflammatory, both acute and chronic, conditions. Furthermore, chronic oxidative stress may modulate iron uptake and storage, leading to a self-sustained and ever-increasing spiral of cytotoxic and mutagenic events. The iron chelator deferroxamine is able to chelate 'free iron' even inside the cell. Its regular clinical use is to promote the excretion of an iron overload, when phlebotomy is harmful, and the dosage varies between 2-10 g/d. In conditions where deferroxamine is used to prevent the iron-driven oxygen toxicity, i.e., acute or chronic inflammatory diseases with oxidative stress, the dosage can be extremely reduced and the addition of antioxidants could be useful. (C) 2001 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 45 条
[1]   Structure and dynamics of the iron responsive element RNA: Implications for binding of the RNA by iron regulatory binding proteins [J].
Addess, KJ ;
Basilion, JP ;
Klausner, RD ;
Rouault, TA ;
Pardi, A .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 274 (01) :72-83
[2]   Medical progress: Disorders of iron metabolism [J].
Andrews, NC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (26) :1986-1995
[3]   FREE-RADICALS AND THE ETIOLOGY OF COLON CANCER [J].
BABBS, CF .
FREE RADICAL BIOLOGY AND MEDICINE, 1990, 8 (02) :191-200
[4]   ON THE LIMITED ABILITY OF SUPEROXIDE TO RELEASE IRON FROM FERRITIN [J].
BOLANN, BJ ;
ULVIK, RJ .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 193 (03) :899-904
[5]   IRON AND THE LIVER [J].
BONKOVSKY, HL .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1991, 301 (01) :32-43
[6]   Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment [J].
Boucher, E ;
Bourienne, A ;
Adams, P ;
Turlin, B ;
Brissot, P ;
Deugnier, Y .
GUT, 1997, 41 (01) :115-120
[7]  
Brittenham G., 1994, Iron Metabolism in Health and Disease, P31
[8]   DEFEROXAMINE THERAPY IN HIGH-FERRITIN DIABETES [J].
CUTLER, P .
DIABETES, 1989, 38 (10) :1207-1210
[9]   Haptoglobin polymorphism, iron metabolism and mortality in HIV infection [J].
Delanghe, JR ;
Langlois, MR ;
Boelaert, JR ;
Van Acker, J ;
Van Wanzeele, F ;
van der Groen, G ;
Hemmer, R ;
Verhofstede, C ;
De Buyzere, M ;
De Bacquer, D ;
Arendt, V ;
Plum, J .
AIDS, 1998, 12 (09) :1027-1032
[10]   Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial [J].
Di Bisceglie, AM ;
Bonkovsky, HL ;
Chopra, S ;
Flamm, S ;
Reddy, RK ;
Grace, N ;
Killenberg, P ;
Hunt, C ;
Tamburro, C ;
Tavill, AS ;
Ferguson, R ;
Krawitt, E ;
Banner, B ;
Bacon, BR .
HEPATOLOGY, 2000, 32 (01) :135-138